Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
复制标题
DOI：
10.12659/msm.906647
复制
发表时间：
2018-05-10
期刊：
影响因子：
--
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Li L;Li X;Meng Q;Khan AQ;Chen X
晚期浆液性卵巢癌导致大多数卵巢癌死亡。组蛋白伴侣，霍利迪连接识别蛋白（HJURP），与着丝粒蛋白-A（CENP-A）结合，其表达已被证明是一些癌症的预后生物标志物。本研究的目的是探讨HJURP在晚期浆液性卵巢癌中的表达。98例晚期浆液性卵巢癌患者，肿瘤组织样本，进行了研究。采用免疫组化（IHC）法检测HJURP的表达水平，并与HJURP表达及患者临床病理因素相关。采用Fisher相关系数、Kaplan-Meier生存曲线、log-rank检验和考克斯回归比例风险模型分析影响生存率的因素和独立预后因素的意义。HJURP在晚期浆液性卵巢癌中的表达率为33.67%（33/98），低表达率为66.33%（65/98）。HJURP的高表达水平与淋巴结转移（P=0.018）和总生存期较低（P=0.002）显着相关。HJURP表达被确定为98例晚期浆液性卵巢癌患者的独立预后生物标志物（P=0.013）。在这项研究中，HJURP的表达增加被确定为晚期浆液性卵巢癌患者的独立阴性预后生物标志物。需要进一步的研究来确定浆液性卵巢癌中HJURP的表达是否可以通过根据风险对患者进行分层来指导临床管理。
Advanced-stage serous ovarian carcinoma results in the majority of deaths from ovarian carcinoma. The histone chaperone, Holliday junction-recognizing protein (HJURP), binds with centromere protein-A (CENP-A) and its expression has been shown to be a prognostic biomarker in some cancers. The aim of this study was to investigate the role of HJURP expression in advanced-stage serous ovarian carcinoma. Ninety-eight patients with advanced-stage serous ovarian carcinoma, who had tumor tissue samples available, were studied. Expression levels of HJURP were detected using immunohistochemistry (IHC) and were correlated with HJURP expression and patient clinicopathological factors. Fisher’s correlation coefficient, Kaplan-Meier survival curves, the log-rank test, and Cox’s regression proportional hazards model were performed to analyze the significance of factors affecting survival rate and independent prognostic factors. Increased expression levels of HJURP in advanced-stage serous ovarian carcinoma were found in 33.67% (33/98) of cases; low expression levels of HJURP were found in 66.33% (65/98) of cases. High expression levels of HJURP were significantly associated with lymph node metastases (P=0.018), and lower overall survival (P=0.002). HJURP expression was identified as an independent prognostic biomarker for patients with advanced serous ovarian cancer in this study group of 98 patients (P=0.013). Increased expression of HJURP was identified as an independent negative prognostic biomarker for patients with advanced serous ovarian cancer in this study. Further studies are required to determine whether HJURP expression in serous ovarian carcinoma may have a role in guiding clinical management by stratifying patients according to risk.